New AI-powered platform helps researchers find promising cancer therapies faster
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Jun-2026 16:15 ET (28-Jun-2026 20:15 GMT/UTC)
A new study led by researchers at WashU Medicine suggests that younger generations are aging biologically faster than their older counterparts. This faster biological aging was also linked to early-onset cancers.
The award, which comes with $100,000, the highest funding level awarded through the OutSmarting Osteosarcoma program, will support Nowicki’s research into the development of a next-generation CAR-T cell therapy for osteosarcoma, the most common bone cancer in children and adolescents.
Researchers at the Icahn School of Medicine at Mount Sinai have found that wearable devices may help clinicians detect cytokine release syndrome (CRS)—a common and potentially serious side effect of CAR-T cell therapy—hours earlier than standard hospital monitoring in patients with multiple myeloma, a blood cancer that begins in plasma cells in the bone marrow.
This study found that conversations between patients and primary care doctors about prostate cancer screening are surprisingly rare, despite national guidelines recommending shared decision-making before screening. MUSC researchers reviewed the records of 600 men ages 45 to 69 years and found that only 6% had a documented discussion about prostate cancer screening in their medical records. However, when those conversations occurred, men were far more likely to undergo prostate-specific antigen (PSA) screening.
The findings were especially notable among Black men, who face a higher risk of dying from prostate cancer. Nearly 85% of Black men who had a documented screening discussion went on to receive a PSA screening test, compared with 36% who did not have such a conversation.
Lead author Nicholas Shungu, M.D., said the study highlights an important gap between screening guidelines and what happens in everyday clinical practice. The research suggests that shared decision-making discussions not only help patients to understand the benefits and limitations of screening but also increase the likelihood that men will choose to be screened.
Immune checkpoint inhibitors (ICIs) are opening a new but complex path for patients with hepatocellular carcinoma (HCC) who may benefit from liver transplantation (LT).
Pre-retrieval imaging is moving liver transplantation toward a more precise and less invasive era.